{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,6,17]],"date-time":"2025-06-17T17:29:32Z","timestamp":1750181372760,"version":"3.37.3"},"reference-count":34,"publisher":"American Diabetes Association","issue":"2","license":[{"start":{"date-parts":[[2022,4,12]],"date-time":"2022-04-12T00:00:00Z","timestamp":1649721600000},"content-version":"vor","delay-in-days":11,"URL":"https:\/\/www.diabetesjournals.org\/journals\/pages\/license"}],"content-domain":{"domain":["diabetesjournals.org"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2022,4,1]]},"abstract":"<jats:p>Sodium\u2013glucose cotransporter 2 (SGLT2) inhibitors are recommended agents for the treatment of diabetic kidney disease (DKD). Additionally, SGLT2 inhibitors lower blood glucose, decrease blood pressure, and can be useful for volume management. For these reasons, we hypothesized that initiating SGLT2 inhibitor therapy may be associated with deprescribing of other medications in patients with DKD. We compared medication lists at SGLT2 inhibitor initiation and 6 months post-initiation in 21 patients with DKD who were followed in our interprofessional outpatient nephrology clinic to evaluate deprescribing patterns in diabetes, hypertension, and diuretic medications. Six months of SGLT2 inhibitor therapy in patients with DKD was associated with deprescribing of high-risk diabetes agents, antihypertensives, and loop diuretics with minimal changes in A1C and fewer adverse events.<\/jats:p>","DOI":"10.2337\/cd21-0078","type":"journal-article","created":{"date-parts":[[2021,10,22]],"date-time":"2021-10-22T16:35:24Z","timestamp":1634920524000},"page":"158-167","update-policy":"https:\/\/doi.org\/10.2337\/ada-journal-policies","source":"Crossref","is-referenced-by-count":3,"title":["Medication Optimization for New Initiators of Empagliflozin for Diabetic Kidney Disease"],"prefix":"10.2337","volume":"40","author":[{"given":"Andrew A.","family":"Swanner","sequence":"first","affiliation":[{"name":"Pharmacy Department, VA Boston Healthcare System, Boston"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Chelsea E.","family":"Hawley","sequence":"additional","affiliation":[{"name":"New England Geriatric Research, Education and Clinical Center, VA Boston Healthcare System, Boston"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kay","family":"Li","sequence":"additional","affiliation":[{"name":"Pharmacy Department, VA Boston Healthcare System, Boston"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8818-9535","authenticated-orcid":false,"given":"Laura K.","family":"Triantafylidis","sequence":"additional","affiliation":[{"name":"Pharmacy Department, VA Boston Healthcare System, Boston"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jiahua","family":"Li","sequence":"additional","affiliation":[{"name":"Renal Section, VA Boston Healthcare System, Boston"},{"name":"Division of Renal (Kidney) Medicine, Department of Medicine, Brigham and Women\u2019s Hospital, Boston, MA"},{"name":"Harvard Medical School, Boston, MA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1315-5445","authenticated-orcid":false,"given":"Julie M.","family":"Paik","sequence":"additional","affiliation":[{"name":"New England Geriatric Research, Education and Clinical Center, VA Boston Healthcare System, Boston"},{"name":"Renal Section, VA Boston Healthcare System, Boston"},{"name":"Division of Renal (Kidney) Medicine, Department of Medicine, Brigham and Women\u2019s Hospital, Boston, MA"},{"name":"Harvard Medical School, Boston, MA"},{"name":"Division of Pharmacoepidemiology and Pharmacoeconomics, Department of Medicine, Brigham and Women\u2019s Hospital, Boston, MA"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"1167","published-online":{"date-parts":[[2022,4,15]]},"reference":[{"key":"2022041519243893200_B1","unstructured":"Centers for Disease Control and Prevention\n          . National Diabetes Statistics Report\u20142020: Estimates of Diabetes and Its Burden in the United States. Available from https:\/\/www.cdc.gov\/diabetes\/data\/statistics-report\/index.html. Accessed 28 September 2021"},{"key":"2022041519243893200_B2","doi-asserted-by":"crossref","first-page":"83","DOI":"10.1186\/s12933-018-0728-6","article-title":"Prevalence of cardiovascular disease in type 2 diabetes: a systematic literature review of scientific evidence from across the world in 2007\u20132017","volume":"17","author":"Einarson","year":"2018","journal-title":"Cardiovasc Diabetol"},{"key":"2022041519243893200_B3","doi-asserted-by":"crossref","first-page":"1984","DOI":"10.2215\/CJN.03700417","article-title":"Diabetes and CKD in the United States population, 2009-2014","volume":"12","author":"Zelnick","year":"2017","journal-title":"Clin J Am Soc Nephrol"},{"key":"2022041519243893200_B4","doi-asserted-by":"crossref","first-page":"2032","DOI":"10.2215\/CJN.11491116","article-title":"Diabetic kidney disease: challenges, progress, and possibilities","volume":"12","author":"Alicic","year":"2017","journal-title":"Clin J Am Soc Nephrol"},{"key":"2022041519243893200_B5","doi-asserted-by":"crossref","first-page":"e005288","DOI":"10.1161\/CIRCHEARTFAILURE.118.005288","article-title":"Prognostic value of albuminuria and influence of spironolactone in heart failure with preserved ejection fraction","volume":"11","author":"Selvaraj","year":"2018","journal-title":"Circ Heart Fail"},{"key":"2022041519243893200_B6","doi-asserted-by":"crossref","first-page":"1738","DOI":"10.2215\/CJN.00580118","article-title":"Medication safety principles and practice in CKD","volume":"13","author":"Whittaker","year":"2018","journal-title":"Clin J Am Soc Nephrol"},{"key":"2022041519243893200_B7","doi-asserted-by":"crossref","first-page":"973","DOI":"10.1007\/s40266-018-0593-8","article-title":"The role of deprescribing in older adults with chronic kidney disease","volume":"35","author":"Triantafylidis","year":"2018","journal-title":"Drugs Aging"},{"key":"2022041519243893200_B8","doi-asserted-by":"crossref","first-page":"E346","DOI":"10.9778\/cmajo.20150131","article-title":"Frequency and cost of potentially inappropriate prescribing for older adults: a cross-sectional study","volume":"4","author":"Morgan","year":"2016","journal-title":"CMAJ Open"},{"key":"2022041519243893200_B9","doi-asserted-by":"crossref","first-page":"638","DOI":"10.1093\/ageing\/afy014","article-title":"Deprescribing: the emerging evidence for and the practice of the \u2018geriatrician\u2019s salute.\u2019","volume":"47","author":"Hilmer","year":"2018","journal-title":"Age Ageing"},{"key":"2022041519243893200_B10","doi-asserted-by":"crossref","first-page":"620","DOI":"10.1093\/ckj\/sfz100","article-title":"Sodium-glucose cotransporter 2 inhibitors for diabetic kidney disease: a primer for deprescribing","volume":"12","author":"Li","year":"2019","journal-title":"Clin Kidney J"},{"key":"2022041519243893200_B11","doi-asserted-by":"crossref","first-page":"644","DOI":"10.1056\/NEJMoa1611925","article-title":"Canagliflozin and cardiovascular and renal events in type 2 diabetes","volume":"377","author":"Neal","year":"2017","journal-title":"N Engl J Med"},{"key":"2022041519243893200_B12","doi-asserted-by":"crossref","first-page":"347","DOI":"10.1056\/NEJMoa1812389","article-title":"Dapagliflozin and cardiovascular outcomes in type 2 diabetes","volume":"380","author":"Wiviott","year":"2019","journal-title":"N Engl J Med"},{"key":"2022041519243893200_B13","doi-asserted-by":"crossref","first-page":"2117","DOI":"10.1056\/NEJMoa1504720","article-title":"Empagliflozin, cardiovascular outcomes, and mortality in type 2 diabetes","volume":"373","author":"Zinman","year":"2015","journal-title":"N Engl J Med"},{"key":"2022041519243893200_B14","doi-asserted-by":"crossref","first-page":"1995","DOI":"10.1056\/NEJMoa1911303","article-title":"Dapagliflozin in patients with heart failure and reduced ejection fraction","volume":"381","author":"McMurray","year":"2019","journal-title":"N Engl J Med"},{"key":"2022041519243893200_B15","doi-asserted-by":"crossref","first-page":"2295","DOI":"10.1056\/NEJMoa1811744","article-title":"Canagliflozin and renal outcomes in type 2 diabetes and nephropathy","volume":"380","author":"Perkovic","year":"2019","journal-title":"N Engl J Med"},{"key":"2022041519243893200_B16","first-page":"1094","article-title":"Empagliflozin, cardiovascular outcomes, and mortality in type 2 diabetes","volume":"374","author":"Zinman","year":"2016","journal-title":"N Engl J Med"},{"key":"2022041519243893200_B17","doi-asserted-by":"crossref","first-page":"S111","DOI":"10.2337\/dc21-S009","article-title":"9. Pharmacologic approaches to glycemic treatment: Standards of Medical Care in Diabetes\u20142021","volume":"44","author":"American Diabetes Association","year":"2021","journal-title":"Diabetes Care"},{"key":"2022041519243893200_B18","doi-asserted-by":"crossref","first-page":"428","DOI":"10.1177\/0897190019876499","article-title":"A pilot study embedding clinical pharmacists within an interprofessional nephrology clinic for the initiation and monitoring of empagliflozin in diabetic kidney disease","volume":"34","author":"Triantafylidis","year":"2021","journal-title":"J Pharm Pract"},{"key":"2022041519243893200_B19","doi-asserted-by":"crossref","first-page":"S55","DOI":"10.2337\/dc18-S006","article-title":"6. Glycemic targets: Standards of Medical Care in Diabetes\u20142018","volume":"41","author":"American Diabetes Association","year":"2018","journal-title":"Diabetes Care"},{"key":"2022041519243893200_B20","doi-asserted-by":"crossref","first-page":"S73","DOI":"10.2337\/dc18-S008","article-title":"8. Pharmacologic approaches to glycemic treatment: Standards of Medical Care in Diabetes\u20142018","volume":"41","author":"American Diabetes Association","year":"2018","journal-title":"Diabetes Care"},{"key":"2022041519243893200_B21","doi-asserted-by":"crossref","first-page":"S139","DOI":"10.2337\/dc19-S012","article-title":"12. Older adults: Standards of Medical Care in Diabetes\u20142019","volume":"42","author":"American Diabetes Association","year":"2019","journal-title":"Diabetes Care"},{"key":"2022041519243893200_B22","doi-asserted-by":"crossref","first-page":"S90","DOI":"10.2337\/dc19-S009","article-title":"9. Pharmacologic approaches to glycemic treatment: Standards of Medical Care in Diabetes\u20142019","volume":"42","author":"American Diabetes Association","year":"2019","journal-title":"Diabetes Care"},{"key":"2022041519243893200_B23","doi-asserted-by":"crossref","first-page":"S61","DOI":"10.2337\/dc19-S006","article-title":"6. Glycemic targets: Standards of Medical Care in Diabetes\u20142019","volume":"42","author":"American Diabetes Association","year":"2019","journal-title":"Diabetes Care"},{"key":"2022041519243893200_B24","doi-asserted-by":"crossref","first-page":"1569","DOI":"10.1161\/CIRCULATIONAHA.119.042685","article-title":"Heart failure risk stratification and efficacy of sodium-glucose cotransporter-2 inhibitors in patients with type 2 diabetes mellitus","volume":"140","author":"Berg","year":"2019","journal-title":"Circulation"},{"key":"2022041519243893200_B25","doi-asserted-by":"crossref","first-page":"S66","DOI":"10.2337\/dc20-S006","article-title":"6. Glycemic targets: Standards of Medical Care in Diabetes\u20142020","volume":"43","author":"American Diabetes Association","year":"2020","journal-title":"Diabetes Care"},{"key":"2022041519243893200_B26","first-page":"S66","article-title":"6. Glycemic targets: Standards of Medical Care in Diabetes\u20142021","volume":"44","author":"American Diabetes Association","year":"2021","journal-title":"Diabetes Care"},{"key":"2022041519243893200_B27","doi-asserted-by":"crossref","first-page":"604","DOI":"10.7326\/0003-4819-150-9-200905050-00006","article-title":"A new equation to estimate glomerular filtration rate","volume":"150","author":"Levey","year":"2009","journal-title":"Ann Intern Med"},{"key":"2022041519243893200_B28","doi-asserted-by":"crossref","first-page":"2773","DOI":"10.2337\/dc07-0717","article-title":"Pioglitazone use and heart failure in patients with type 2 diabetes and preexisting cardiovascular disease: data from the PROactive study (PROactive 08)","volume":"30","author":"Erdmann","year":"2007","journal-title":"Diabetes Care"},{"key":"2022041519243893200_B29","doi-asserted-by":"crossref","first-page":"2545","DOI":"10.1056\/NEJMoa0802743","article-title":"Effects of intensive glucose lowering in type 2 diabetes","volume":"358","author":"Action to Control Cardiovascular Risk in Diabetes Study Group","year":"2008","journal-title":"N Engl J Med"},{"key":"2022041519243893200_B30","doi-asserted-by":"crossref","first-page":"231","DOI":"10.1016\/j.kint.2017.06.017","article-title":"Pooled analysis of phase III trials indicate contrasting influences of renal function on blood pressure, body weight, and HbA1c reductions with empagliflozin","volume":"93","author":"Cherney","year":"2018","journal-title":"Kidney Int"},{"key":"2022041519243893200_B31","doi-asserted-by":"crossref","first-page":"750","DOI":"10.1016\/j.kint.2020.10.031","article-title":"Characterization and implications of the initial estimated glomerular filtration rate \u2018dip\u2019 upon sodium-glucose cotransporter-2 inhibition with empagliflozin in the EMPA-REG OUTCOME trial","volume":"99","author":"Kraus","year":"2021","journal-title":"Kidney Int"},{"key":"2022041519243893200_B32","doi-asserted-by":"crossref","first-page":"115","DOI":"10.1016\/S2213-8587(18)30313-9","article-title":"Change in albuminuria and subsequent risk of end-stage kidney disease: an individual participant-level consortium meta-analysis of observational studies","volume":"7","author":"Coresh","year":"2019","journal-title":"Lancet Diabetes Endocrinol"},{"key":"2022041519243893200_B33","first-page":"1","article-title":"KDIGO 2012 clinical practice guideline for the evaluation and management of chronic kidney disease","volume":"3","author":"Kidney Disease: Improving Global Outcomes (KDIGO) CKD Work Group","year":"2013","journal-title":"Kidney Int Suppl"},{"key":"2022041519243893200_B34","doi-asserted-by":"crossref","first-page":"653","DOI":"10.1007\/s40620-018-0502-6","article-title":"Chronic hyperkalemia in non-dialysis CKD: controversial issues in nephrology practice","volume":"31","author":"De Nicola","year":"2018","journal-title":"J Nephrol"}],"container-title":["Clinical Diabetes"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/diabetesjournals.org\/clinical\/article-pdf\/40\/2\/158\/672927\/diaclincd210078.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/diabetesjournals.org\/clinical\/article-pdf\/40\/2\/158\/672927\/diaclincd210078.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,4,15]],"date-time":"2022-04-15T19:25:32Z","timestamp":1650050732000},"score":1,"resource":{"primary":{"URL":"https:\/\/diabetesjournals.org\/clinical\/article\/40\/2\/158\/138900\/Medication-Optimization-for-New-Initiators-of"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,4,1]]},"references-count":34,"journal-issue":{"issue":"2","published-online":{"date-parts":[[2022,4,15]]},"published-print":{"date-parts":[[2022,4,1]]}},"URL":"https:\/\/doi.org\/10.2337\/cd21-0078","relation":{},"ISSN":["0891-8929","1945-4953"],"issn-type":[{"type":"print","value":"0891-8929"},{"type":"electronic","value":"1945-4953"}],"subject":[],"published":{"date-parts":[[2022,4,1]]}}}